Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.
about
Personalized treatment of advanced non-small-cell lung cancer in routine clinical practiceComprehensive genomic characterization of squamous cell lung cancers.AKT1E¹⁷K Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung CancerHigh Expression of Rab-like 3 (Rabl3) is Associated with Poor Survival of Patients with Non-Small Cell Lung Cancer via Repression of MAPK8/9/10-Mediated AutophagySurvival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study).Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancerUsage patterns of biomarkers in non-small-cell lung cancer patients in India: Findings from a systematic review and survey.Non-small cell lung cancer histological subtype has prognostic impact in patients with brain metastases.Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort studyβV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancerThe prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis.Cetuximab in non-small-cell lung cancerManagement of elderly patients.A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (tMLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinomaSuitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients.A modified experimental model of malignant pleural disease induced by lung Lewis carcinoma (LLC) cells.Mutant AKT1-E17K is oncogenic in lung epithelial cellsRandomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancerRole of deltaNp63(pos)CD44v(pos) cells in the development of N-nitroso-tris-chloroethylurea-induced peripheral-type mouse lung squamous cell carcinomas.Targeting genomic alterations in squamous cell lung cancer.Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer.The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?Exome sequencing identifies frequent mutation of MLL2 in non-small cell lung carcinoma from Chinese patients.Disparities in subgroup populations enrolled in lung cancer trials.Maintenance therapy for advanced non-small-cell lung cancer: ready for clinical practice?Hotspot oncomutations: implications for personalized cancer treatment.An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.Clinical relevance of the new IASLC/ERS/ATS adenocarcinoma classification.Molecular cytogenetics: recent developments and applications in cancer.2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?Autophagy enhanced the radioresistance of non-small cell lung cancer by regulating ROS level under hypoxia condition.Combined point mutation in KRAS or EGFR genes and EML4-ALK translocation in lung cancer patients.Milestones in the systemic treatment of lung cancerGuidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.
P2860
Q28075800-DC00AB13-9CF2-4DCF-8DFA-B72E65090BF9Q28274701-AFEB1C78-20CC-4743-B56E-8A04B7647250Q28550038-E49C5B6B-A989-4AA2-B1BC-945961AAAEEBQ28829201-B10CD246-1155-4D32-81B8-D0F02C3EF87EQ30683030-EB8C8384-85CC-48D9-9C9F-DF123DA7D21CQ33577811-B97BBC4D-B4AD-4C93-B425-0CC7AB26BDAAQ34031517-16AEF53A-0098-4465-B569-5F9F0D4FC26EQ34216371-77C060D2-B365-43A1-8A8C-25A095BB5B21Q34235130-DA438EE4-A802-42A7-AF64-BA1B16A4C08EQ34353248-F20349AD-43B3-4626-9A57-5F3D28F113AFQ35140489-0AA2A596-7C68-47BE-B450-1DE5AEB8298AQ35200393-106C81E3-86C3-4038-B027-6E5DB6B621FBQ35200398-4F44AE72-C139-448A-92A6-ACE0CE4D25D2Q35527102-C6F3C2BD-B53D-4F1B-AD9F-611F554EAE5EQ35781614-C068BA95-1D94-4BA1-9607-82FB055F6B64Q36043762-90095153-9B01-4853-BF41-C62E74A8F315Q36066547-6B451B40-0C28-49CC-8E1B-3D0B84EE9E98Q36545440-98100BC5-2937-4524-B779-F18D14874BDFQ36557454-56C2FA87-384D-42A7-A492-2B5C3794FB2BQ36622102-FDB55C97-23EB-4FA8-9561-9935E445F0FAQ37068767-12AD1C62-20AB-4681-A4B3-598B6118A6EDQ37539257-480049A4-9D80-46F9-8DB7-6A23F5B62FBAQ37709481-89117451-536D-4220-ABD7-A80A3BF7BE22Q37735770-8FFF1DB3-0A28-4B0D-AF82-CD72DB8ED2B9Q37738412-38A22021-FD6A-45CD-A25D-A019E2748201Q37997817-ADC37D4B-5866-4A68-902D-641747C18692Q38002474-8FC5A589-98ED-40FB-ACCE-B8E408802457Q38030603-2B825F7D-F1DA-4851-8235-06FF5341535DQ38077494-FB63A3F8-7BA9-4F20-987D-004E192133F9Q38097027-5500557E-0979-4261-BD65-67790D8C0722Q38119502-5A827E7B-466B-4018-81A5-68D86F80F24EQ38190426-05387C64-4C58-49CF-A646-B3358CD1425BQ38199478-D154AD89-72C9-4223-927D-8E7DA1F0770AQ38203468-F7317886-4E5C-4F66-9A50-3EEE588F2497Q38232942-1051090F-0B7C-4E17-A91E-306B2210CD16Q38705244-700E51EF-7E39-4248-B793-F64CBAE3011CQ39205782-1AB7C5FF-DF2C-464B-8A7A-FF23E557E61AQ39214395-52DF13B0-9673-411C-9BA4-F4D8BB7FDDB1Q39622232-C9884DDF-753C-4296-BAE1-0A78061C8F59Q42214080-63715A15-B908-4D8B-AD2E-109946C86EC0
P2860
Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Metastatic non-small-cell lung ...... e in Lung Cancer; Lugano 2010.
@en
Metastatic non-small-cell lung ...... e in Lung Cancer; Lugano 2010.
@nl
type
label
Metastatic non-small-cell lung ...... e in Lung Cancer; Lugano 2010.
@en
Metastatic non-small-cell lung ...... e in Lung Cancer; Lugano 2010.
@nl
prefLabel
Metastatic non-small-cell lung ...... e in Lung Cancer; Lugano 2010.
@en
Metastatic non-small-cell lung ...... e in Lung Cancer; Lugano 2010.
@nl
P2093
P2860
P356
P1433
P1476
Metastatic non-small-cell lung ...... e in Lung Cancer; Lugano 2010.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDR150
P577
2011-05-02T00:00:00Z